Could This News Spark a Turnaround for Ocugen?

Could This News Spark a Turnaround for Ocugen?
·4 min read

Ocugen (NASDAQ: OCGN) shares were flying high earlier this year. The company signed a deal with India's Bharat Biotech for co-commercialization rights to its coronavirus vaccine candidate in the U.S. The Bharat product was close to market. Since then, Ocugen learned it wouldn't win the right to sell the vaccine in the U.S. as soon as it had hoped.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting